Eupraxia’s EP-104GI Shows Promise in EoE Trial

Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.

Eupraxia Pharmaceuticals Inc. reported positive outcomes from the RESOLVE Phase 1b/2a trial of EP-104GI for Eosinophilic Esophagitis, showing symptom improvement in most patients. The fourth cohort delivered the most significant changes in histology scores, with no serious adverse events reported. These promising results suggest EP-104GI, administered via Eupraxia’s DiffuSphere™ technology, could offer a new treatment option for EoE.

For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.